Realizing the Potential for Recipient Immune Cells in Adoptive Immune Therapy  by Qazi, Sanjive
EBioMedicine 10 (2016) 11–12
Contents lists available at ScienceDirect
EBioMedicine
j ourna l homepage: www.eb iomed ic ine.comCommentaryRealizing the Potential for Recipient Immune Cells in Adoptive
Immune TherapySanjive Qazi
Biology Department, Gustavus Adolphus College, Saint Peter, MN 56082, United StatesDOI of original article: http://dx.doi.org/10.1016/j.ebi
E-mail address: sqazi@gustavus.edu.
http://dx.doi.org/10.1016/j.ebiom.2016.07.003
2352-3964/© 2016 Published by Elsevier B.V. This is an opa r t i c l e i n f oArticle history:
Received 4 July 2016
Accepted 4 July 2016
Available online 6 July 2016
this grade of morbidity requires further third-line interventions such
as administration of mTOR inhibitors, anti-TNF antibodies, IL-2 receptor
antibodies and mesenchymal stem cell transplantation (Dignan et al.,
2012). RLI has the potential to markedly reduce the occurrence of
graft versus host disease that is observed with DLI (Saito et al., 2006).
Since one of the ultimate goals of allogenic-HSCT for treating hemato-Despite the extensive use of animalmodels to better understand dis-
ease progress, efﬁcacy and toxicity of therapeutic interventions a vast
majority of promising treatments fail in human trials (Holzapfel et al.,
2015). One approach has been to humanizemousemodel systems to re-
capitulate disease processes by conditioning mice to permit engraft-
ment of human cells utilizing immune-deﬁcient mice such as NSG
strains (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) in pre-clinical studies. One
major advantage of this is to allow detailed molecular proﬁling of dis-
eased cells and targeting aberrant processes for individual patients by
growing patient derived cells xenografted into immune-deﬁcient mice
(Malaney et al., 2014). However, major shortcoming of humanized xe-
nograft mouse models include: the absence of a tumor microenviron-
ment to study cytokine/chemokine interactions that are critical for
cancer progression and metastasis; and toxicity arising from induction
of cytokine storms cannot be tested.
To expand the use of xenograft models in preclinical studies by
reconstituting human hematopoietic and lymphoid immune systems,
Xia et al. (2016) report ﬁndings from a proof of principle studywhereby
humanized mice were transplanted with human fetal thymic tissue
(FTHY) in and followed the progression of leukemia using stem cells de-
rived from CD34+ fetal liver cells (FLCs) transduced with leukemia as-
sociated fusion gene MLL-AF9. These humanized mice developed B-cell
Acute Lymphoblastic Leukemia (B-ALL) that could be transferred to a
secondary recipient with an autologous immune system to assess the
anti-leukemic efﬁcacy of recipient leukocyte infusion (RLI), which is
an anti-tumor response from the “host” immune system as opposed to
the more commonly used technique of donor leukocyte infusion (DLI)
that exhibits anti-tumor activity from allogenic T-cells. DLI has proven
very useful treatment option resulting in remission following hemato-
poietic stem cell transplantation (HSCT), but also induces toxic graft
versus host disease (GVHD). A multicenter report from UK reports
that up to 71% of cases (68 cases examined) developed GVHD and halfom.2016.06.028.
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logical malignancies is to separate graft versus leukemia and graft ver-
sus host disease mechanisms induced by donor T-cells, RLI provides a
means to achieve this goal.
Xia et al. (2016) compellingly demonstrated that NSG mice develop
a human immune system and leukemia, and further show that RLI me-
diated anti-leukemia activity in the presence of lymphopenia conditions
presenting the translational research communitywith a tractablemodel
system to study leukocyte infusions for immune therapies. Conditioning
for HSCT can result in long lasting lymphopenia (Daikeler et al., 2012)
thereby limiting the use of DLI, but permitting the use of RLI as a poten-
tial treatment strategy. In this investigation, NSGwere conditionedwith
2Gy total body irradiation and transplanted with CD34+ FLCs and thy-
mic tissue fragments. These humanizedmice developed B-ALL and ﬂow
cytometric analysis conﬁrmed reconstitution of human peripheral
blood mononuclear, T-subtype, B-subtype and myeloid immune cells
in this model system. Transplantation of ‘recipient’ FTHY and CD34+
FLCs intoNSGmiceprovided a source for RLI treatment utilized to inves-
tigate anti-leukemic potential of the recipient immune system against
autologous (‘recipient’) and allogenic (‘donor’) mixed chimera mice.
Mixed chimera mice were made from ‘donor’ CD34+ FLCs (obtained
from a different fetal liver than the one for the RLI source), recipient
CD34+ FLCs and recipient thymic tissue. RLI treatment of these MCs
did not exhibit a strong host versus graft reaction. However, one of
the signiﬁcant ﬁndings of this study suggested a strong host versus
graft reaction could be elicited upon removal of the recipient thymic
tissue or depletion of T cells in the MC to mimic lymphopenia, boosting
themyeloid count by increasing the production of human cytokines via
hydrodynamic injection of cytokine containing plasmids and depleting
regulatory T-cells using anti-human CD25 microbeads. In this response
the proportion of donor CD45+ T-cells was markedly reduced and the
recipient population of CD3+ cells was increased after 4 weeks of RLI
treatment. RLI treatment resulted in the loss of donor CD45 and CD19
cells that was more pronounced in lymphopenic MCs. This ability to
manipulate the cytokine stimulation and to selectively populate the
engraftment of immune cells entertains the possibility of designing-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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and Treg cells in reducing GVHD and enhancing anti-leukemic effects
(MacDonald et al., 2016; Pierini et al., 2016).
Clinical signiﬁcance of this ﬁnding was demonstrated by the knock-
down of GFP labelled leukemia cells following 7 weeks of treatments
and expansion of the activated/memory phenotype CD45RA−/
CD45RO+ T-cells. The humanized mouse model system reported by
Xia et al. (2016) has the potential to further investigate the dynamics
and timing of the emergence of different T-cell populations involved
in effect or function, proliferative capacity, memory formation and im-
mune reconstitution central to delivering effective adoptive immune
therapies. For example basic ontological questions concerning linear
differentiation model, decreasing potential model or progression
models can be directly examined for RLI therapy (Busch et al., 2016)
providing clues to which populations of T-cells can be harnessed to en-
hance anti-leukemic effects while reducing GVHD.
Moving forward into the clinical setting, it still needs to be elucidat-
ed how RLI therapy can be sourced and administered to patients. The
molecular features and mechanisms of RLI action once characterized
could be used to generate the cellular sources for adoptive immune
therapies utilizing recipient cells.
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